1) 日本神経内分泌腫瘍研究会(JNETS)膵・消化管神経内分泌腫瘍診療ガイドライン第2版作成委員会 編:膵・神経内分泌腫瘍(NEN)診療ガイドライン 2019(第2版). 金原出版, 2019
2) Lloyd RV, Osamura RY, Kloppel G et al:WHO classification of tumours of endo-crine organs. In:Lloyd RV, editor. WHO classification of tumours. vol.10, 4th ed, Lyon:International Agency for Research on Cancer, 2017
3) Gill A, Klimstra D, Lam A et al:WHO classification of tumours:digestive sys-tem tumours. 5th ed, Lyon:International Agency for Research on Cancer, 2019
4) Hijioka S, Hosoda W, Matsuo K et al:Rb loss and KRAS mutation are predic-tors of the response to platinum-based chemotherapy in pancreatic neuroendo-crine neoplasm with grade 3:A Japanese multicenter pancreatic NEN-G3 study. Clin Cancer Res 23:4625-4632, 2017
5) Ito T, Jensen RT:Molecular imaging in neuroendocrine tumors:recent advances, controversies, unresolved issues, and roles in management. Curr Opin Endocrinol Diabetes Obes 24:15-24, 2017
6) Ito T, Hijioka S, Masui T et al:Advances in the diagnosis and treatment of pancre-atic neuroendocrine neoplasms in Japan. J Gastroenterol 52:9-18, 2017
7) Adams LC, Bressem KK, Brangsch J et al:Quantitative 3D assessment of 68Ga-DOTATOC PET/MRI with diffusion-weighted imaging to assess imaging markers for gastroenteropancreatic neuro-endocrine tumors:Preliminary results. J Nucl Med 61:1021-1027, 2020
8) Hicks RJ, Dromain C, de Herder WW et al:ENETS standardized(synoptic)re-porting for molecular imaging studies in neuroendocrine tumours. J Neuroendocri-nol:e13040, 2021
9) Ito T, Fujimori N, Honma Y et al:Long-term safety and efficacy of lanreotide autogel in Japanese patients with neuroen-docrine tumors:Final results of a phase II open-label extension study. Asia Pac J Clin Oncol 17:e153-e161, 2021
10) Ikeda M, Morizane C, Hijioka S et al:Optimal strategy of systemic treatment for unresectable pancreatic neuroendocrine tumors based upon opinion of Japanese experts. Pancreatology 20:944-950, 2020
11) Shibuya H, Hijioka S, Sakamoto Y et al:Multi-center clinical evaluation of streptozocin-based chemotherapy for ad-vanced pancreatic neuroendocrine tumors in Japan:focus on weekly regimens and monotherapy. Cancer Chemother Pharma-col 82:661-668, 2018
12) Strosberg J, El-Haddad G, Wolin E et al;NETTER-1 Trial Investigators:Phase 3 Trial of 177Lu-Dotatate for midgut neuroen-docrine tumors. N Engl J Med 376:125-135, 2017
13) Kobayashi N, Wild D, Kaul F et al:Retro-spective study of peptide receptor radio-nuclide therapy for Japanese patients with advanced neuroendocrine tumors. J Hepa-tobiliary Pancreat Sci 28:727-739, 2021
14) 膵・消化管神経内分泌腫瘍(NEN)診療ガイドライン 第2版(2021年7月改訂);内科・集学的治療 CQ9:膵・消化管 NENに対して放射線治療は推奨されるか? 改訂版 http://jnets.umin.jp/pdf/cq9_nen.pdf
15) Pavel M, Jann H, Prasad V et al:NET blood transcript analysis defines the cross-ing of the Clinical Rubicon:When stable disease becomes progressive. Neuroendo-crinology 104:170-182, 2017
16) Genc CG, Jilesen APJ, Nieveen van Dijkum EJM et al:Measurement of circulating transcript levels(NETest)to detect disease recurrence and improve follow-up after curative surgical resection of well-differentiated pancreatic neuroendocrine tumors. J Surg Oncol 118:37-48, 2018
17) Modlin IM, Kidd M, Frilling A et al:Mo-lecular genomic assessment using a blood-based mRNA signature(NETest)is cost-effective and predicts neuroendocrine tumor recurrence with 94%accuracy. Ann Surg 274:481-490, 2021
18) Oberg K, Califano A, Strosberg JR et al:A meta-analysis of the accuracy of a neuroendocrine tumor mRNA genomic biomarker(NETest)in blood. Ann Oncol 31:202-212, 2020
19) Kudo A, Akahoshi K, Ito S et al:Down-regulated pancreatic beta cell genes indicate poor prognosis in patients with pancreatic neuroendocrine neoplasms. Ann Surg 271:732-739, 2020
20) Miki M, Oono T, Fujimori N et al:CLE-C3A, MMP7, and LCN2 as novel markers for predicting recurrence in resected G1 and G2 pancreatic neuroendocrine tumors. Cancer Med 8:3748-3760, 2019
21) Pavel M, Oberg K, Falconi M et al:Gastroenteropancreatic neuroendocrineneoplasms:ESMO Clinical PracticeGuidelines for diagnosis, treatment andfollow-up. Ann Oncol 31:844-860, 2020
22) Ito T, Masui T, Komoto I et al:JNETSclinical practice guidelines for gastro-enteropancreatic neuroendocrine neo-plasms:diagnosis, treatment, and follow-up:a synopsis. J Gastroenterol 56:1033-1044, 2021
23) Masui T, Ito T, Komoto I et al:Recent epi-demiology of patients with gastro-entero-pancreatic neuroendocrine neoplasms(GEP-NEN)in Japan:a population-based study. BMC Cancer 20:1104, 2020
24) Aoki T, Kubota K, Kiritani S et al:Survey of surgical resections for neuroendocrine liver metastases:A project study of the Japan Neuroendocrine Tumor Society(JNETS). J Hepatobiliary Pancreat Sci 28:489-497, 2021